8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Oct 30, 2025)

Filed October 30, 2025For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) has filed a Current Report on Form 8-K to announce its financial results for the quarter ended September 30, 2025. The report primarily serves as a vehicle to furnish the accompanying press release, which contains the detailed financial outcomes for the period. Investors should refer to the press release (Exhibit 99.1) for the specific revenue, earnings, and other key financial metrics. While this 8-K filing itself does not contain the detailed financial data, it signifies the official public disclosure of Alnylam's performance for the third quarter of 2025. The company's forward-looking statements within the press release, if any, would be crucial for assessing future prospects, but are not directly presented in the 8-K filing's core text. Investors are encouraged to review the furnished press release for a comprehensive understanding of the company's operational and financial standing as of and for the quarter ended September 30, 2025.

Key Highlights

  • 1Alnylam Pharmaceuticals, Inc. (ALNY) announced Q3 2025 financial results on October 30, 2025.
  • 2The 8-K filing primarily furnishes the press release containing the financial results.
  • 3Investors must consult Exhibit 99.1 (the press release) for specific financial performance data.
  • 4The filing is a standard disclosure of quarterly earnings.
  • 5Information furnished in Item 2.02 is not deemed 'filed' for certain regulatory purposes.
  • 6Key performance indicators (revenue, EPS, etc.) are detailed in the separate press release.

Frequently Asked Questions

The specific financial results for the quarter ended September 30, 2025, are detailed in the press release furnished as Exhibit 99.1 to this Form 8-K filing. You will need to access that document for the detailed figures.

When information is furnished under Item 2.02, it is generally not considered 'filed' for the purpose of Section 18 of the Securities Exchange Act of 1934. This means the company may have less liability for that specific information compared to information that is formally filed with the SEC, though it is still important for investors to consider.

This 8-K filing is primarily focused on the announcement of financial results. Any business updates or strategic changes would typically be found within the content of the press release (Exhibit 99.1) itself, not in the core text of the 8-K filing. Investors should carefully review the press release for such details.